Skip to main content
RLYB
NASDAQ Life Sciences

5AM Ventures Significantly Reduces Stake in Rallybio Corp Post-Reverse Split

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$7.54
Mkt Cap
$39.815M
52W Low
$1.761
52W High
$7.78
52W Position info
328% above low
Off High info
3.1% below high
Rel. Volume info
3.1× avg
Market data snapshot near publication time

RLYB has more than doubled off its 52-week low of $1.761 on elevated volume (3.1× avg).

Summary

Institutional investor 5AM Ventures sold approximately $983,000 worth of Rallybio Corp shares, significantly reducing its stake after the recent reverse stock split.


Key Events · Ownership and Investor Activity · RLYB

  • Significant Share Sales by Institutional Investor

    5AM Ventures sold a total of 162,052 shares of Rallybio Corp common stock in open market transactions on February 25 and 26, 2026.

  • Substantial Value of Sales

    The sales generated approximately $983,000 in proceeds, representing a significant reduction in the investor's position.

  • Post-Reverse Stock Split Activity

    These transactions occurred shortly after Rallybio Corp's 1-for-8 reverse stock split, which was effective on February 2, 2026, and was intended to help the company meet Nasdaq's minimum bid price requirement.

  • Reduced Beneficial Ownership

    Following these sales, the 5AM Ventures group's aggregate beneficial ownership in Rallybio Corp has been significantly reduced to 5.5% of the outstanding common stock.


Analysis · RLYB · Life Sciences

5AM Ventures, a major institutional investor, has significantly reduced its stake in Rallybio Corp by selling approximately $983,000 worth of shares. These sales, representing over 2.4% of the company's market capitalization and more than 50% of 5AM Ventures' reported aggregate holdings, occurred shortly after the company's 1-for-8 reverse stock split. This substantial reduction by a key investor, following a critical corporate action aimed at maintaining Nasdaq listing, could signal a lack of long-term conviction and may exert further selling pressure on the stock.

At the time of this filing, RLYB was trading at $7.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.8M. The 52-week trading range was $1.76 to $7.78. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RLYB - Latest Insights

RLYB
Jul 15, 2026, 5:20 PM EDT
Filing Type: S-4
Importance Score:
9
Price at Filing: $16.13
Real-time Price: $16.16 info
Change: +$0.025 (+0.15%) info
Market Cap: $85.622M info
RLYB
Jun 01, 2026, 8:09 AM EDT
Filing Type: 425
Importance Score:
10
Price at Filing: $14.46
Real-time Price: $16.16 info
Change: +$1.70 (+12%) info
Market Cap: $85.622M info
RLYB
Jun 01, 2026, 8:07 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $14.46
Real-time Price: $16.16 info
Change: +$1.70 (+12%) info
Market Cap: $85.622M info
RLYB
Jun 01, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $14.46
Real-time Price: $16.16 info
Change: +$1.70 (+12%) info
Market Cap: $85.622M info
RLYB
May 15, 2026, 8:49 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $14.30
Real-time Price: $16.16 info
Change: +$1.86 (+13%) info
Market Cap: $85.622M info